Publications by authors named "Mark Bookbinder"

Claim this Profile
C
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models".
Michael Berlin, Jennifer Cantley, Mark Bookbinder, Elizabeth Bortolon, Fabio Broccatelli

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.
Sheryl M Gough, John J Flanagan, Jessica Teh, Monica Andreoli, Emma Rousseau, Mark Bookbinder

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROTACs Targeting BRM (SMARCA2) Afford Selective Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.
Michael Berlin, Jennifer Cantley, Mark Bookbinder, Elizabeth Bortolon, Fabio Broccatelli

J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies.
Amy Easton, Marianne L Jensen, Congwei Wang, Peter H Hagedorn, Yuwen Li, Mark Bookbinder

Mol Ther Nucleic Acids· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.
Michael R Weed, Joseph Polino, Laura Signor, Mark Bookbinder, Deborah Keavy

PLoS One· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of ()-3-((3,4)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate -Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.
Linda J Bristow, Jyoti Gulia, Michael R Weed, Bettadapura N Srikumar, Yu-Wen Li, Mark Bookbinder

J Pharmacol Exp Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains.
Michael R Weed, Mark Bookbinder, Joseph Polino, Deborah Keavy, Rudolf N Cardinal

Neuropsychopharmacology· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis